Long-term data confirm overall survival benefit with zoledronic acid. Women five years postmenopause had greatest benefit. Even delayed use of zoledronic acid reduced recurrence vs. no use. SAN ANTONIO — The addition of zoledronic acid to adjuvant endocrine...
Filed under: Press Releases, Research, Breast Cancer, Conference, Cancer, teleconference, Media Materials, AACR, American Association for Cancer Research, women, meeting, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, Richard de Boer, Zoledronic acid, early, postmenopausal